COMT genotype and response to cognitive remediation in schizophrenia

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 279-284

  Lindenmayer, Jean Pierre ^a,b,c   Khan, Anzalee ^a,c,d   Lachman, Herbert ^e   McGurk, Susan R ^f   Goldring, Abraham ^a,c   Thanju, Amod ^a,c   Kaushik, Saurabh ^g  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d ProPhase LLC   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f BOSTON UNIVERSITY   (United States)

^g NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cognitive remediation; COMT genotype; Schizophrenia; Social cognition

Indexed keywords

CATECHOL METHYLTRANSFERASE; COMT PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ADULT; ALERTNESS; ARTICLE; CATECHOL O METHYLTRANSFERASE GENE; CLINICAL TRIAL; COGNITIVE REMEDIATION THERAPY; DSM-IV-TR; FEMALE; GENOTYPE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SALIVA ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; THERAPY EFFECT; TREATMENT DURATION; VISION; COGNITIVE THERAPY; GENETIC POLYMORPHISM; GENETICS; GENOTYPING TECHNIQUE; MULTIMODALITY CANCER THERAPY; NEUROPSYCHOLOGICAL TEST; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; SALIVA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SALIVA; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84942365348     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.07.037     Document Type: Article

References (35)

1. Arnsten A. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb. Cortex 2007, 17(Suppl. 11):i6-i15.
2. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in subjects with schizophrenia. Am. J. Psychiatry 2004, 161(110):1798-1805.
3. Bosia M., Bechi M., Pirovano A., Buonocore M., Lorenzi C., Cocchi F., Bramanti P., Smeraldi E., Cavallaro R. COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia. Health Psychol. Behav. Med. 2014, 2(1):509-516.
4. Bosia M., Marino E., Bechi M., Anselmetti S., Poletti S., Cocchi F., Smeraldi E., Cavallaro R. Influence of catechol-O-methyl transferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci. Lett. 2007, 417:271e274.
5. Bosia M., Zanoletti A., Spangaro M., Buonocore M., Bechi M., Cocchi F., Pirovano A., Lorenzi C., Bramanti P., Smeraldi E., Cavallaro R. Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment. Psychiatry Res. 2014, 30(1-2):9-14.
6. De la Vega F.M., Lazaruk K.D., Rhodes M.D., Wenz M.H. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP genotyping assays and the SNPlex genotyping system. Mutat. Res. 2005, 573(571 572):111-535.
7. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(12):6917-6922.
8. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153(153):321-330.
9. Greenwood K., Hung C.F., Tropeano M., McGuffin P., Wykes T. No association between the catechol-O-methyltransferase (COMT) val158met polymorphism and cognitive improvement following cognitive remediation therapy (CRT) in schizophrenia. Neurosci. Lett. 2011, 496:65-69.
10. Harrison P., Tunbridge E. Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 2007, 33:3037-3045.
11. Hironori K., Takanori U. Neuronal Mechanisms of Visual Perceptual Learning 2013, 10.1016/j.bbr.2013.1004.1034.
12. Ira E., Zanoni M., Ruggeri M., Dazzan P., Tosato S. COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation. J. Psychiatry Neurosci. 2013, 38(36):366-380.
13. Jennions M.D., Møller A.P. A survey of the statistical power of research in behavioral ecology and animal behavior. Behav. Ecol. 2003, 14:438-445.
14. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6(3):243-250.
15. Lindenmayer J.P., McGurk S.R., Mueser K.T., Khan A., Wance D., Hoffman L., Wolfe R., Xie H. A randomized controlled trial of cognitive remediation among in subjects with persistent. Mental Illness Psychiatric 2008, 200241-200247. (Services200859:200853).
16. Littell R.C., M.G., Stroup W.W., Wolfinger R.D. SAS System for Mixed Models 1996, SAS Institute Inc, Cary, NC.
17. Lotta J., Vidgren C., Tilgmann I., Ulmanen K., Melen I., Julkunen J., Taskinen Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4204.
18. Malhotra A.K., Kestler L.J., Mazzanti C., Bates J.A., Goldberg D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am. J. Psychiatry 2002, 159(154):652-654.
19. McGurk S.R., Mueser K.T. Cognitive functioning, symptoms, and work in supporter employment: a review and heuristic model. Schizophr. Res. 2004, 70:147-173.
20. McGurk S.R., Mueser K.T., DeRosa T., Wolfe R. Work, recovery, and comorbidity in schizophrenia. Schizophr. Bull. 2009, 35(32):319-335.
21. McGurk S.R., Mueser K.T., Pascaris A. Cognitive training and supported employment for persons with severe mental illness: one year results from a randomized controlled trial. Schizophr. Bull. 2005, 31:898-909.
22. McGurk S.R., Twamley E.W., Sitzer D., McHugo G. A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatr. 2007, 164:1791-1802.
23. Meyer-Lindenberg A., Nichols T., Callicott J.H., Ding J., Kolachana B., Buckholtz J., Mattay V.S., Egan M., Weinberger D.R. Impact of complex genetic variation in COMT on human brain function. Mol. Psychiatry 2006, 11. (867-77, 797).
24. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S., Kraemer H., Mesholam-Gately R., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165:203-213.
25. Panizzutti R., Hamilton S.P., Vinogradov S. Genetic correlate of cognitive training response in schizophrenia. Neuropharmacology 2013, 64:264e267.
26. Professional Version Marker Software Klaus Marker L. COGPACK 2004.
27. Sartory G., Zorn C., Groetzinger G., Windgassen K. Computerized cognitive rehabilitation improves verbal learning and processing speed in schizophrenia. Schizophr. Res. 2005, 75:219-223.
28. Stoehr A.M. Are significance thresholds appropriate for the study of animal behaviour?. Anim. Behav. 1999, 57:F22-F25.
29. Weickert T.W., Goldberg T.E., Mishara A., Apud J.A., Kolachana B.S., Egan M.F., Weinberger D.R. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 2004, 56(59):677-682.
30. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., Berman K.F., Goldberg T.E. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry 2001, 1(50(11):825-844.
31. Wilkinson G.S. The Wide Range Achievement Test: Manual 1993, Wide Range, Wilmington, DE. 3rd ed.
32. Wirgenes K.V., Djurovic S., Sundet K. Catechol O-methyltransferase variants and cognitive performance in schizophrenia and bipolar disorder versus controls. Schizophr. Res. 2010, 122(121-123):131-137.
33. Wonodi I., Stine O.C., Mitchell B.D., Buchanan R.W., Thaker G.K. Association between Val108/158 met polymorphism of the COMT gene and schizophrenia. Am. J. Med. Genet. 2003, 120B:147-150. 10.1002/ajmg.b.20037.
34. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 2011, 168(5):472-485. 10.1176/appi.ajp.2010.10060855.
35. Wykes T., Reeder C., Corner J., Wiliams C., Everitt B. The effects of neurocognitive remediation on executive processing in subjects with schizophrenia. Schizophr. Bull. 1999, 25(22):291-307.